To test the hypothesis that PP2A inhibition synergizes with aPD-1 therapy in vivo in aPD-1 refractory tumors, we used CT26 tumor, which is a murine colorectal carcinoma with high PD-L1 expression but limited response to aPD-1 therapy16. Here, CD274 is linked to colorectal carcinoma.